Johan M. Spoor Buys 22,026 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the purchase, the chief executive officer now owns 59,383 shares of the company’s stock, valued at approximately $133,017.92. This represents a 58.96 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Perspective Therapeutics Price Performance

CATX stock opened at $1.96 on Wednesday. The stock’s 50 day simple moving average is $2.88 and its 200 day simple moving average is $6.10. Perspective Therapeutics, Inc. has a 12-month low of $1.90 and a 12-month high of $19.05.

Institutional Trading of Perspective Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC boosted its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Millennium Management LLC acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $4,132,000. State Street Corp grew its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Octagon Capital Advisors LP raised its position in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CATX. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Finally, Royal Bank of Canada reduced their price target on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $14.44.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.